Universities and research institutes at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
101 universities and research institutes are at ASH 2026 — 112 presentations on the program. Most represented: Stanford University (10 on the program), University of Pennsylvania (9 on the program), Washington University in St. Louis (7 on the program). 44 of them have their own page in this guide. As of Sep 27, 2026.
Topic
Top represented
Showing 1–4 of 101 organizations
| Organization | ASH 2026 Attendance |
|---|---|
Stanford University Stanford, CA | |
Private research university in Stanford, California, including its School of Medicine. | Symposium Fri Dec 11 7:00am–10:00am A Hematologist’s Guide to the Sickle Cell Disease Revolution: Genes, Activators, and Beyond Approved and emerging gene therapies and new pyruvate kinase activators for sickle cell disease, and how to match patients to each and refer them. Session AI Models of Cell State for the Design of Next-Generation T Cell Therapies Using AI trained on patient data to predict which T cell states make CAR-T therapy work, moving cell design beyond trial and error. Talk Clinically Informed AI Models for Predicting and Engineering CAR T Cell Function Predicting which lymphoma patients respond to CAR-T from single-cell RNA profiles of the infused cells, then simulating better designs on a computer. Talk New Standards in GVHD Prophylaxis: Towards a Future Without GVHD Newer ways to prevent graft-versus-host disease after donor transplants, such as engineered cell grafts, abatacept, and post-transplant cyclophosphamide. Talk Clonal Hematopoiesis of Indeterminate Potential and Arterial Thrombosis: Mechanisms and Clinical Implications How clonal hematopoiesis alters myeloid cells to promote atherosclerosis, and how to evaluate affected patients for heart attack and stroke risk. Session From Mutations to Manifestations: Connecting Clonal Hematopoiesis (CH) and Thrombosis How clonal hematopoiesis, the age-related spread of mutated blood cells, fuels inflammation and artery and vein clots, and whether anti-inflammatory drugs help. Talk Targeted Therapies: From Genomic Insights to Therapeutic Strategies Genomic insights behind three targeted drug classes for childhood acute myeloid leukemia: blockers of B-cell lymphoma 2, menin and fms-like tyrosine kinase 3. Talk Treatment Sequencing After CAR-T Failure in Multiple Myeloma Choosing the next treatment for multiple myeloma that relapses after CAR-T cell therapy, weighing key clinical factors and approved and emerging options. Session Showcasing a Decade of Discoveries in Blood Advances Ten years of the hematology journal Blood Advances, revisiting its most influential clinical trials, basic science studies and practice guidelines. Talk Limitations and Risks of Generative AI Where generative AI fails in medicine, from hallucinations and bias to rare-disease blind spots, and how validation, governance, and human oversight reduce harm. Session Session Session Session |
University of Pennsylvania Philadelphia, PA | |
Private research university in Philadelphia, home to the Perelman School of Medicine. | Symposium Fri Dec 11 7:00am–10:00am B-Cell–Directed Therapies in Immune Thrombocytopenia: Real-World Practice Newer B-cell-targeting treatments for immune thrombocytopenia and how to fit them into care to achieve lasting platelet responses. Symposium Fri Dec 11 3:00pm–6:00pm Evidence at Every Step: Applying the Latest CAR T-Cell Data Across the NHL Care Continuum Getting relapsed lymphoma patients to CAR-T sooner, with earlier referral, bridging therapy, sequencing choices, and management of immune and nerve toxicities. Talk Rational Design of FVIII Variants for Gene Therapy: Linking Molecular Insight to Therapeutic Performance Engineering a better version of the clotting protein missing in hemophilia A for gene therapy, balancing stronger bleeding control against clot risk. Session JOINT SESSION - New Horizons in RNA Biology in Myeloid Development and Malignancy Every stage of the RNA life cycle, from splicing to chemical marks, shapes blood stem cells and blood cancers, pointing to new treatments. Talk Beyond Remission: Long-Term Hematopoietic Toxicity and Second Malignancies After CAR-T Cell Therapy Persistently low blood counts and second cancers after CAR-T therapy, including their frequency, causes, and how to monitor, prevent, and manage them. Talk Flt3 inhibitors in newly diagnosed and relapsed patients Evidence behind current Flt3 inhibitor use in newly diagnosed and relapsed acute myeloid leukemia, and where investigational approaches are heading. Talk Indications and Timing of Splenectomy in Hereditary Hemolytic Anemia When and how to remove the spleen in inherited red cell membrane and enzyme disorders, weighing benefit against lifelong infection and clotting risks. Session |
Washington University in St. Louis St. Louis, MO | |
Private research university in St. Louis, Missouri, including the WashU School of Medicine. | Symposium Fri Dec 11 7:00pm–10:00pm Addressing Community Oncologists’ Questions About Novel Therapies in Non-Hodgkin Lymphoma – What Clinicians Want To Know: A CME-Accredited Friday Satellite Symposium Preceding the 68th ASH Annual Meeting Answers to community oncologists' most pressing questions about new drugs for non-Hodgkin lymphoma, drawn from a survey and reviewed against current research. Symposium Fri Dec 11 11:00am–2:00pm Best Practice Use of Bispecific Antibodies in Non-Hodgkin Lymphoma – A Second Opinion Case Review Difficult non-Hodgkin lymphoma cases treated or considered for bispecific antibodies, with reviews of recent data, current practice, and ongoing trials. Session Special Symposium on the Basic Science of Hemostasis and Thrombosis (SSBSHT) New tools including multiomics, protein design, functional genomics, and AI applied to how blood clots form and dissolve, and to bleeding disorders. Talk Structural Insights into Mechanisms How an enzyme chemically modifies vitamin K dependent proteins, and how that step shapes blood clotting control, bone building, and blood vessel signaling. Session Rethinking Antiplatelet Strategies: Selective Blockade, Broad-Acting Drugs, and Beyond Safer clot prevention by selectively blocking the platelet signals that grow a clot, instead of shutting platelets down and raising bleeding risk. Talk Vascular Anomalies: Understanding the Healthcare Experiences of Patients and Caregivers What living with a rare vascular anomaly involves, from long diagnostic journeys and stigma to scarce experts, and how clinicians can help. Talk Hematopoietic Stem Cell Transplantation in Severe Congenital Hemolytic Anemias Using stem cell transplants from matched or mismatched donors, now safer, to cure severe inherited hemolytic anemias, even in very young children. Talk Update on the management of Extensive DVT Recent trials on managing extensive deep vein thrombosis, and which patients benefit from catheter-directed clot removal for acute or chronic clots. |
UCSF San Francisco, CA | |
University of California's health sciences campus in San Francisco, focused on medicine, biomedical research and graduate health education. | Symposium Fri Dec 11 7:00pm–10:00pm Advancing the DLBCL Paradigm: Sequencing Bispecifics in Optimizing Patient Care Where bispecific antibodies fit in diffuse large B-cell lymphoma, weighed against CAR-T by patient fitness, access, and T-cell health. Symposium Fri Dec 11 3:00pm–6:00pm Medical Crossfire®: Strategic Sequencing in ALL — From Asparaginase to Cellular Therapy in an MRD-Driven Era Ordering acute lymphoblastic leukemia therapies, from asparaginase to bispecifics and CAR-T, guided by sensitive residual disease testing. Talk Promoting the Peacekeepers: Treg Adoptive Therapies to Re-Establish Tolerance Regulatory T cells redirected with chimeric antigen receptors to restore immune tolerance in rheumatoid arthritis, from lab studies to clinical findings. Talk Bispecific Antibodies OR CAR-T in Early Relapse for Multiple Myeloma Comparing CAR-T cells with off-the-shelf bispecific antibodies for early-relapse myeloma, weighing trial evidence, risks, and the best treatment order. |
Instantly find 20 buyers from universities and research institutes
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ASH 2026 by
Organization type
Topic
- Leukemias, MDS & MPN 110
- Lymphoma & CLL 81
- Myeloma & Amyloidosis 74
- Bispecifics, ADCs & Targeted Drugs 92
- Transplant, Cell & Gene Therapy 86
- Sickle Cell, Anemia & Red Cell Disorders 76
- Bleeding, Clotting & Platelets 53
- Stem Cells & Blood Biology 52
- AI, Genomics & Data 42
- Clinical Practice & Access to Care 87
Exhibit hall
Everyone
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction